Ohio State Navbar


TCL-1 transgenic mouse model for natural history of CLL

Through an exclusive agreement with Dr. Carlo Croce and collaborators at The Ohio State University, we have pioneered a transgenic mouse model of CLL that was generated by introducing the human TCL1 gene under control of a B cell-specific Ig promoter. TCL1 transgenic mice develop a monoclonal B-cell lymphocytosis that is very similar to human CLL in immunophenotypic and clinical features as well as response to fludarabine. Development of the TCL-1 mouse provides the Byrd Lab a suitable animal model of CLL to adequately assess pharmacologic properties relevant to clinical application.

Selected Papers:

Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC*, Lucas DM*. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leukemia Research 2007; 31(12):1737-40. *Co-senior authors

Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, Croce CM, Grever MR, Byrd JC. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006; 108(4):1334-8

Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, and Plass C. (2009) “Epigenetic alterations in a murine model for chronic lymphocytic leukemia”. Cell Cycle. 8(22):3663-7/a>